TrovaGene (TROV) Gets a Buy Rating from Maxim Group

By Carrie Williams

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on TrovaGene (TROVResearch Report), with a price target of $8. The company’s shares opened today at $3.13, close to its 52-week low of $2.54.

McCarthy noted:

“Trovagene announced that the company will present two posters from its two lead clinical programs evaluating Onvansertib (a polo-like kinase inhibitor, PLK inhibitor) in acute myeloid leukemia (AML) and metastatic castration- resistant prostate cancer (mCRPC) at this year’s American Association for Cancer Research (AACR) Annual Meeting on March 29-April 3 in Atlanta.”

According to, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.0% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TrovaGene with a $6.50 average price target, representing a 107.7% upside. In a report issued on February 20, Noble Financial also maintained a Buy rating on the stock with a $5 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $34.20 and a one-year low of $2.54. Currently, TrovaGene has an average volume of 349.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.